13-32380005-A-G
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PVS1PP3_StrongPP5_Very_Strong
The NM_000059.4(BRCA2):c.9118-2A>G variant causes a splice acceptor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000991 in 1,613,896 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000059.4 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BRCA2 | NM_000059.4 | c.9118-2A>G | splice_acceptor_variant | ENST00000380152.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.9118-2A>G | splice_acceptor_variant | 5 | NM_000059.4 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152180Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000319 AC: 8AN: 250530Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135638
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1461716Hom.: 0 Cov.: 32 AF XY: 0.00000688 AC XY: 5AN XY: 727150
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152180Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74348
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:9
Pathogenic, no assertion criteria provided | clinical testing | BRCAlab, Lund University | Aug 26, 2022 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA2) | Jun 22, 1999 | - - |
Pathogenic, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Jun 18, 2019 | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on posterior probability = 0.994466 - |
Pathogenic, criteria provided, single submitter | clinical testing | Department of Medical Genetics, Oslo University Hospital | Jul 01, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge | Oct 02, 2015 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2000 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | Sep 21, 2015 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | Jul 22, 2013 | - - |
Hereditary breast ovarian cancer syndrome Pathogenic:3
Pathogenic, no assertion criteria provided | research | Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto | Jan 31, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 07, 2020 | Variant summary: BRCA2 c.9118-2A>G is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 3' acceptor site and creates a 3' acceptor site. Experimental evidence supports that this variant affects mRNA splicing (Machackova_2008, Acedo_2012). The variant allele was found at a frequency of 3.2e-05 in 250530 control chromosomes. c.9118-2A>G has been reported in the literature in multiple individuals affected with Hereditary Breast and Ovarian Cancer (ie Rebbeck_2018). These data indicate that the variant is very likely to be associated with disease. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jun 09, 2022 | For these reasons, this variant has been classified as Pathogenic. Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 22632462). ClinVar contains an entry for this variant (Variation ID: 52759). This variant is also known as 9346-2A>G. Disruption of this splice site has been observed in individual(s) with breast cancer and/or ovarian cancer (PMID: 9150152, 29339979, 29446198). It has also been observed to segregate with disease in related individuals. This variant is present in population databases (rs81002862, gnomAD 0.04%). This sequence change affects an acceptor splice site in intron 23 of the BRCA2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 10, 2018 | This variant is denoted BRCA2 c.9118-2A>G or IVS23-2A>G and consists of an A>G nucleotide substitution at the -2 position of intron 23 of the BRCA2 gene. Using alternate nomenclature, this variant has previously been published as BRCA2 9346-2A>G. This variant destroys a canonical splice acceptor site and is predicted to cause abnormal gene splicing, leading to either an abnormal message that is subject to nonsense-mediated mRNA decay or to an abnormal protein product. This variant has been reported in high risk breast/ovarian cancer families and is reported to be a Finnish founder variant (Vehmanen 1997, Huusko 1998, Sarantaus 2000, Janavicius 2010, Kluska 2015). Both RT-PCR and minigene assays have demonstrated aberrant splicing as a result of BRCA2 c.9118-2A>G (Claes 2003, Acedo 2012). Based on the current evidence, we consider this variant to be pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 02, 2022 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 11, 2023 | The c.9118-2A>G intronic pathogenic mutation results from an A to G substitution two nucleotides upstream from coding exon 23 in the BRCA2 gene. This alteration has been reported in multiple familial breast/ovarian cancer cohorts, and has been described as a Finnish founder mutation (Loman N et al. J. Natl. Cancer Inst. 2001 Aug;93:1215-23; Heramb C et al. Hered Cancer Clin Pract. 2018 Jan;16:3; Sarantaus L et al. Int. J. Oncol. 2001 Apr;18:831-5; Huusko P et al. Am. J. Hum. Genet. 1998 Jun;62:1544-8; Sarantaus L et al. Eur. J. Hum. Genet. 2000 Oct;8:757-63; Vehmanen P et al. Am. J. Hum. Genet. 1997 May;60:1050-8; Kluska A et al. BMC Med Genomics. 2015 May;8:19). Minigene and RT-PCR functional studies have demonstrated exon skipping (Acedo A et al. Breast Cancer Res. 2012 May;14:R87) and production of an aberrant transcript lacking the first 7 base pairs of exon 24, resulting in a premature stop codon (Claes K et al. Genes Chromosomes Cancer. 2003 Jul;37:314-20), respectively. Of note, this alteration is also designated as 9346-2ntA>G and IVS23-2A>G in the published literature. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Feb 10, 2022 | This variant causes an A to G nucleotide substitution at the -2 position of intron 23 of the BRCA2 gene. Functional RNA studies have shown that this variant causes the activation of an out-of-frame cryptic acceptor site, resulting in a premature termination signal and truncated protein (PMID: 12759930, 18489799, 22632462). This variant has been reported in 17 female individuals affected with breast cancer, 8 male individuals affected with breast cancer, 2 individuals affected with ovarian cancer (PMID: 10995809, 11251181, 11504767, 12759930, 15548363, 15642173, 18489799) and has been identified in 21 families among the CIMBA participants (PMID: 29446198). In a large breast cancer case-control study conducted by the BRIDGES consortium, this variant was reported in 6/60466 cases and 0/53461 controls; p-value=0.033; Leiden Open Variation Database DB-ID BRCA2_000410 (PMID: 33471991). This variant is a known founder mutation in the Finnish European population and has been identified in 8/250530 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at